Status:

RECRUITING

PATH Program for for Severely Frail or Cognitively Impaired Patients Scheduled for Cancer Surgery.

Lead Sponsor:

Nova Scotia Health Authority

Conditions:

Frailty

Oncology Problem

Eligibility:

All Genders

75+ years

Phase:

NA

Brief Summary

This is a single center, non-blinded randomized control trial taking place at the Queen Elizabeth II hospital (QEII) in Nova Scotia. Patients are eligible if aged 75 and older scheduled for elective c...

Detailed Description

At Nova Scotia Health Authority (NSHA), geriatric medicine colleagues developed a preoperative palliative and therapeutic harmonization (PATH) clinic with the following objectives: 1. Assess medical ...

Eligibility Criteria

Inclusion

  • Patients must have a clinically highly suspicious or pathologically confirmed diagnosis of bronchopulmonary, oropharyngeal (including head and neck surgery), orthopaedic, gynaecological, breast, genitourinary or gastrointestinal cancer surgery.
  • Patients must be scheduled and consented for curative or palliative intent surgery.
  • Patients must be aged 75 or older.
  • Patients must be screened by the CFS to have:
  • 4a. Mild or greater frailty (CFS equal or greater than 5) due to cognitive impairment.
  • 4b. Moderate or greater frailty (CFS equal or greater than 6) due to medical/physical conditions.
  • 5\. Informed consent for participation must be received.

Exclusion

  • Patients cannot be a resident in a long-term care facility prior to the cancer diagnosis.
  • Urgent/ emergent cases are excluded.

Key Trial Info

Start Date :

January 31 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2026

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT06022666

Start Date

January 31 2024

End Date

March 1 2026

Last Update

August 23 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

QEII, Victoria General Hospital

Halifax, Nova Scotia, Canada, B3H 2Y9